Duchenne muscular dystrophy is the latest rare disease market to attract the attention of investors and big pharma. It may also be the launching pad for the next turbo-charged small-cap developer, as Sarepta Therapeutics Inc. demonstrated recently with its release of promising Phase IIB results.
Numerous assets addressing a variety of biological targets – early and late stage, partnered and unpartnered – are advancing through...